Temozolomide (TMZ) is most commonly used for the treatment of primary glioblastoma but is now being considered for the treatment of low-grade glioma that harbor mutations in the cytosolic isocitrate dehydrogenase 1 (IDH1) gene. Though the treatment of IDH1 mutant patients with TMZ improves survival, there is a need for complementary metabolic imaging approaches to help in assessing early response to therapy. Hyperpolarized 13C magnetic resonance spectroscopy-based metabolic profiling of mutant IDH1 cells treated with TMZ revealed that [1-13C]/[5-13C] glutamate production from [1-13C] α-ketoglutaric acid/[2-13C] pyruvate could serve as translatable biomarkers of response to therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords